China’s biotechnology market has “significantly” driven up the demand for primate experimental models as the market recovers, tightening the supply of laboratory monkeys, according to a leading biotech firm.
Primate experiments typically use monkeys and other non-human species to test the safety and efficacy of a drug under development before clinical trials on humans.
Over US$110 billion worth of Chinese-developed drug candidates were traded in 81 out-licensing deals in the first half of the year, equivalent to 80 per cent of the full-year value in 2025, data from China’s National Medical Products Administration showed.
Joinn added that the price increase resulted from the tightened supply of non-human primates for experimental use in China, as their breeding rate has remained relatively stable.


Don't Miss:
-
Drug Trafficking, U.S. Banks, and the Economic Reality Under Trump
-
Ivan’s Mob Beheads A Los Mayos Member
-
Ex-OFAC Official: The Cartel Risk Companies Can’t See | The InSight Take
-
Why Ecuador Is Losing Its Fight Against Organized Crime
-
‘El Cromo’ Arrested in Guadalajara; He Is Linked to a Group Affiliated with the CJNG

The Taliban’s New War Begins at Home
Panama removed from EU’s tax haven ‘blacklist’ a decade after the Panama Papers
Crackdown and Controversy: The Battle Over Beach Bars and Noise in Phuket’s Bang Tao